EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[Lymphoma. À§Àå°ü ¸²ÇÁÁ¾] - ðû

±è¼®Áø ±³¼öÀÇ °­ÀÇ


1. À§Àå°ü ¸²ÇÁÁ¾¿¡ ´ëÇÑ ÇÊÀÚÀÇ ÂªÀº Á¾¼³

PDF, 0.9 M


2. À§Àå°ü ¸²ÇÁÁ¾ ³»½Ã°æ Áø´Ü¿¡ ´ëÇÑ ±ØÈ÷ °³ÀÎÀû »ý°¢ (2016-12-9)

À§Àå°ü ¸²ÇÁÁ¾Àº ´Ù¾çÇÕ´Ï´Ù. Çѵΰ³ÀÇ °øÅëµÈ Ư¡ÀÌ ¾ø½À´Ï´Ù. ±³°ú¼­¿¡´Â ´ÙÀ½°ú °°ÀÌ ¾º¿© ÀÖ½À´Ï´Ù.

Endoscopic findings described in the textbook (Yamada eds.)

1) Gastric lymphoma can be grossly indistinguishable from adenocarcinoma, but is actually a diffusely infiltrating submucosal lesion.

2) The tumor may present as a polypoid lesion with ulcerations, but like other submucosal lesions, the overlying mucosa may traverse the mass as a characteristic bridging fold.

3) Lymphomas do not have a predilection for any particular region of the stomach, but are more likely than other cancers to present with diffuse infiltration and enlarged rugal folds.

±×·¯³ª ±³°ú¼­ÀÇ ¼³¸í¸¸À¸·Î´Â ÃæºÐÇÏÁö ¾ÊÀº °Í °°½À´Ï´Ù. ±×·¡¼­ °³ÀÎÀûÀÎ ÀÇ°ßÀ» ºÙÀÔ´Ï´Ù.

1) À§Àå°ü ¸²ÇÁÁ¾Àº Á¡¸·ÇϺ´¼Òó·³ º¸ÀÌ´Â °æ¿ìµµ ÀÖÀ¸³ª Á¡¸·º´¼ÒÀÎ °æ¿ì°¡ ´õ ¸¹½À´Ï´Ù.

2) ¾Æ·¡¿Í °°Àº °æ¿ì¿¡´Â ¸²ÇÁÁ¾À» ÀǽÉÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù.

¸²ÇÁÁ¾ÀÇ º´¸®ÇÐÀû Áø´Ü¿¡´Â ¾Æ·¡ÀÇ algorithmÀ» Âü°íÇϽñ⠹ٶø´Ï´Ù.

Çؼ³

¸²ÇÁÁ¾Àº Á¾·ù°¡ ¸¹¾Æ¼­ ¾î¶»°Ô Á¢±ÙÇÏ´Â °ÍÀÌ ÁÁÀ»Áö ÆÇ´ÜÀÌ ¾î·Æ½À´Ï´Ù. ¾Æ·¡¿Í °°Àº ¼ø¼­¸¦ ±ÇÇÕ´Ï´Ù.

  1. B ¼¼Æ÷ÀÎÁö T ¼¼Æ÷ÀÎÁö ±¸ºÐÇÑ´Ù. --> T ¼¼Æ÷¸é ´ëºÎºÐ Ç×¾ÏÄ¡·á
  2. B ¼¼Æ÷ Áß MALT ¸²ÇÁÁ¾ÀÎÁö ¾Æ´ÑÁö ±¸ºÐÇÏ´Ù. --> MALT ¸²ÇÁÁ¾ÀÌ¸é ´ëºÎºÐ Helicobacter Á¦±ÕÄ¡·á
  3. ´Ù¸¥ °ÍµéÀº °¢ÀÚ °³º° Áø´Ü¿¡ µû¶ó Ä¡·áÇÑ´Ù.


3. °ËÁø³»½Ã°æ¿¡¼­ ¹ß°ßµÇ´Â ¿ø¹ß¼º À§¸²ÇÁÁ¾

¼­¿ï´ëÇб³ °­³²¼¾ÅÍ¿¡¼­ °ËÁø³»½Ã°æ¿¡¼­ ¹ß°ßµÈ ¿ø¹ß¼º À§¸²ÇÁÁ¾¿¡ ´ëÇÑ ³í¹®À» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù (Yang HJ. JGH 2016 - Epub).

Results: Of the 105,194 recipients of screening upper endoscopy, 52 (0.049%) were found to have PGL. The median age was 54.2 years (range 23-79), and 65.4% were female. The proportion of PGL to gastric malignancy was 12.1% (52/429) overall, but >30% (25/73) in middle-aged (40-59) females. PGLs in the screening group were more likely to be mucosa-associated lymphoid tissue (MALT) lymphoma (98.1% vs. 60.0%, P < 0.001) and treated with H. pylori eradication alone (90.0% vs. 48.1%, P < 0.001) than those in the outpatient group.

10¸¸ 5õ¿©¸íÀÇ °ËÁø ³»½Ã°æ Áß 429¸í(0.41%)¿¡¼­ À§¾ÏÀÌ ¹ß°ßµÇ¾ú½À´Ï´Ù. 250¸í °ËÁø³»½Ã°æ¿¡¼­ ÇÑ ¸íÀÇ À§¾ÏÀÌ ¹ß°ßµÈ ¼ÀÀÌ´Ï ¿ì¸®³ª¶ó ´ëÇüº´¿øÀÇ Æò±ÕÀûÀÎ ¼öÄ¡¿´½À´Ï´Ù. ±× Áß 12.1%(52/429)°¡ À§¸²ÇÁÁ¾À̾úÀ¸¸ç DLBCL (diffuse large B cell lymphoma) ÇÑ ¸í »©°í ¸ðµÎ Àúµµ MALT ¸²ÇÁÁ¾À̾ú½À´Ï´Ù. Àú´Â ¹«Áõ»ó gastric DLBCL¸¦ ¿©·¯¸í Áø·áÇÑ ¹Ù Àִµ¥ ´ëºÎºÐ ¾îµð¼±°¡ °ËÁø ³»½Ã°æ ÈÄ ÀÇ·ÚµÈ È¯ÀÚµéÀ̾ú½À´Ï´Ù. ±×·¡¼­ 52¸í Áß ÇÑ ¸íÀ̶ó´Â ¼öÄ¡°¡ Á¶±Ý ³·°Ô ´À²¸Á³½À´Ï´Ù.

¾Æ·¡´Â ³í¹®¿¡¼­ Á¦½ÃµÈ progression free survivalÀÔ´Ï´Ù. ºñ·Ï p value 0.399·Î Åë°èÀû Â÷ÀÌ°¡ ¾ø¾úÁö¸¸ °ÇÁø¹ß°ß ¸²ÇÁÁ¾¿¡ ºñÇÏ¿© ¿Ü·¡ ȯÀÚ Àúµµ ¸²ÇÁÁ¾ÀÇ progression free survivalÀÌ ´õ ³ªºüº¸Àδٴ Á¡ÀÌ Æ¯ÀÌÇß½À´Ï´Ù. ¿Ü·¡ ȯÀÚ Àúµµ ¸²ÇÁÁ¾ÀÇ »ó´ç¼ö°¡ Ÿ º´¿ø °ÇÁø¹ß°ß ¸²ÇÁÁ¾ÀÏ °ÍÀε¥ ¸»ÀÔ´Ï´Ù.

¼­¿ï´ë °ËÁøÀÇ ³í¹®À» º¸´Ï ¹®µæ ¿À·¡µÈ Áõ·Ê Çϳª°¡ »ý°¢³³´Ï´Ù. 2008³â 6¿ù 2ÀÏ '¿À´ÃÀÇ Áõ·Ê'¿´½À´Ï´Ù. °ËÁø ³»½Ã°æ¿¡¼­ DLBCLÀÌ ¹ß°ßµÇ¾î Ç×¾ÏÄ¡·á¸¦ Çߴµ¥ ±×¸¸ õ°øÀÌ ¹ß»ýÇÑ °æ¿ì¿´½À´Ï´Ù. ȯÀڴ óÀ½ºÎÅÍ Ãµ°ø¹ß»ý½Ã±îÁö ¹«Áõ»óÀ̾ú´Âµ¥ Á¶±Ý ¹Ì¾ÈÇß½À´Ï´Ù. °ËÁø ³»½Ã°æÀ» ÇÏ´Ùº¸¸é ÀÌó·³ ¹Ì¾ÈÇÑ °æ¿ì°¡ Á¾Á¾ ¹ß»ýÇÕ´Ï´Ù. ¾Ö½Ã´çÃÊ Áõ»óÀÌ ¾ø´ø »ç¶÷À̹ǷΠġ·á¸¦ Çؼ­ ´õ ÇູÇÏ°Ô ¸¸µé±â´Â ¹«Ã´ ¾î·Á¿î ÀÏÀÔ´Ï´Ù. ´ç½ÃÀÇ À̹ÌÁö¿Í ¼³¸íÀ» ¿Å±é´Ï´Ù.

Screening endoscopyÀÇ ¸ñÀûÀº ¼ö¼úÀ̳ª EMR/ESD·Î Ä¡·áÇÒ ¼ö ÀÖ´Â À§¼±¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â °ÍÀÔ´Ï´Ù. À§¸²ÇÁÁ¾À» Áø´ÜÇϱâ À§ÇÏ¿© screening endoscopy¸¦ ½ÃÇàÇÏ´Â °ÍÀº ¾Æ´Õ´Ï´Ù¸¸ °£È¤ MALToma³ª DLBCL µîÀÌ Áø´ÜµÇ±âµµ ÇÕ´Ï´Ù. ¹«Áõ»ó DLBCLÀ» ¾î¶»°Ô Ä¡·áÇÏ´Â °ÍÀÌ ÁÁÀºÁö¿¡ ´ëÇÑ consensus´Â ¾ø½À´Ï´Ù. ÇöÀç·Î¼­´Â Áõ»óÀÌ ÀÖ¾î ½ÃÇàÇÑ °Ë»ç¿¡¼­ ¹ß°ßµÇ´Â DLBCL¿¡ ÁØÇÏ¿© Ä¡·á¸¦ ÇÏ°í ÀÖ½À´Ï´Ù.

ÃÖ±Ù ¸î¸î ³í¹®¿¡¼­ GI lymphomaÀÇ chemotherapy ÈÄ perforationÀÇ À§ÇèÀÌ °ú°Å¿¡ »ý°¢ÇÏ¿´´ø °Íº¸´Ù ³ôÁö ¾Ê´Ù´Â ÁÖÀåÀÌ ÀÖ¾ú½À´Ï´Ù. ±×·¯³ª º» Áõ·Êó·³ ¾ÆÁ÷µµ °£È¤ chemotherapy ÈÄ perforationÀÌ ¹ß»ýÇϱ⵵ ÇÕ´Ï´Ù. Ä¡·á¸¦ ½ÃÀÛÇϱâ Àü¿¡ ¹Ýµå½Ã ȯÀÚ¿¡ ÀÌ·¯ÇÑ À§ÇèÀ» ¾Ë¸®´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.


[2016-2-11. ³í¹® ÀúÀڷκÎÅÍÀÇ ´äº¯]

¼±»ý´Ô ¾È³çÇϼ¼¿ä. À̹ø¿¡ ÀúÈñ ¼¾ÅÍ¿¡¼­ ³ª¿Â ³í¹®À» ¼Ò°³ÇØÁּż­ °¨»çÇÕ´Ï´Ù.

¾ÆÁ÷±îÁö À§¾Ï °ËÁø ³»½Ã°æ¿¡¼­ ¹ß°ßµÇ´Â À§¸²Æ÷¸¶ÀÇ ºóµµ³ª ¿¹ÈÄ¿¡ ´ëÇÑ ³í¹®Àº °ÅÀÇ ¾ø¾ú´ø °ü°è·Î ¼¾ÅÍ °³¿ø 10ÁÖ³âÀ» ¸ÂÀÌÇÏ¿© °ËÁø³»½Ã°æ¿¡¼­ À§¾Ï »Ó¾Æ´Ï¶ó maltoma¸¦ Æ÷ÇÔÇÑ À§¸²Æ÷¸¶ÀÇ ºóµµ°¡ ¾î¶»°Ô µÉ °ÍÀÎÁö¿¡ ´ëÇÑ ±Ã±ÝÁõÀ¸·Î ½ÃÀÛÇÑ ¿¬±¸ÀÔ´Ï´Ù.

À§¾Ï Áß ¸²Æ÷¸¶°¡ 12.1%·Î Áö±Ý±îÁöÀÇ º¸°í¿¡ ºñÇØ »ó´çÈ÷ ³ôÀº ¼öÁØÀ» º¸¿´À¸¸ç ´ëºÎºÐ(27/52) erosion ÇüÅ¿´½À´Ï´Ù. ¼±»ý´Ô ¸»¾¸´ë·Î DLBLÀÌ »ý°¢º¸´Ù Àû¾ú´Âµ¥ ÀÏ´Ü Àüü °ËÁø À§¸²Æ÷¸¶ ¼ýÀÚ°¡ 50¸íÀ¸·Î Àû°í Áö±Ý±îÁö º°·Î ¿¬±¸°¡ ¾ø±â ¶§¹®¿¡ Á¤È®ÇÑ prevalence¿¡ ´ëÇؼ­´Â ¹¹¶ó°í °á·Ð³»¸®±â ¾î·Æ½À´Ï´Ù.

¿Ü·¡ low grade maltoma¿Í °ËÁø low grade maltoma¿¡¼­ prognosisÀÇ Â÷ÀÌ°¡ ÀÖ¾ú´ø Á¡Àº ÀúÈñ °ËÁø¿¡¼­ ±âÁ¸ÀÇ ¿¬±¸º¸´Ù incidence°¡ ³ô¾Ò°í, µû¶ó¼­ ¹ß°ßµÈ maltomaº´º¯ÀÌ ÀÛÀº erosionÇüŸ¦ ¸¹ÀÌ Æ÷ÇÔÇÑ Á¶±âº´º¯À¸·Î ¿Ü·¡ maltomaº¸´Ù disease burdenÀÌ Àû¾ú´ø °ÍÀÌ ¾Æ´Ñ°¡ »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù.

¿Ü·¡ ¸²ÇÁÁ¾ ȯÀÚµéÀÇ Áø´Ü°æ·Î³ª Áõ»ó¿©ºÎ¸¦ ÆľÇÇÒ ¼ö ÀÖ¾úÀ¸¸é ´õ ÁÁÀº ¿¬±¸°¡ µÇ¾ú°ÚÁö¸¸ Çö½ÇÀûÀÎ ¾î·Á¿òÀ¸·Î ŸÇùÇÏ¿´½À´Ï´Ù.

ÀúÈñ ¿¬±¸¿¡¼­ µ¶Æ¯Çß´ø Á¡Àº ³²ÀÚ¿Í ´Þ¸® ¿©¼º¿¡¼­´Â Á߳⿩¼º(40-59)¿¡¼­ °¡Àå ³ô°í ÀÌÈķδ °¨¼ÒÇÏ´Â ¾ç»óÀ» º¸Àδٴ Á¡ÀÔ´Ï´Ù. ¾ÆÁ÷ ¿øÀÎÀ» ¶Ñ·ÇÇÏ°Ô Á¦½ÃÇÏ±ä ¾î·Æ°í ´Ù¸¥ ¼¾Å͵鵵 ºñ½ÁÇÑ ¼Ò°ßÀ» º¸ÀÏÁö selection bias°¡ ÀÛ¿ëÇÑ °ÍÀÎÁö ±Ã±ÝÇϱä ÇÕ´Ï´Ù.

°á·ÐÀûÀ¸·Î À§¾Ï°ËÁø ¸ñÀûÀ¸·Î ½ÃÇàÇÏ´Â ³»½Ã°æ¿¡¼­ maltoma¸¦ ºñ·ÔÇÑ À§¸²ÇÁÁ¾µµ »ý°¢º¸´Ù ¸¹ÀÌ ¹ß°ßµÇ±â ¶§¹®¿¡ ³»½Ã°æ ÀÇ»ç´Â Ç×»ó °ü½ÉÀ» °¡Áö°í Àû±ØÀûÀ¸·Î Á¶Á÷°Ë»ç¸¦ Çغ¸´Â °ÍÀÌ ÇÊ¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù. maltoma´Â °£´ÜÇÑ Ä¡·á·Î ÇØ°áÇÒ ¼ö ÀÖ°í DLBL·Î ÁøÇàÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.

»õÇØ º¹ ¸¹ÀÌ ¹ÞÀ¸¼¼¿ä.


[Cases]

Dysphagia°¡ ÀÖ´Ù°í ¸ðµÎ ½Äµµ ÁúȯÀº ¾Æ´Õ´Ï´Ù. Dysphagia°¡ ÀÖ¾î ¼ÒÈ­±â³»°ú ¿Ü·¡¸¦ ¹æ¹®ÇϼÌÀ¸³ª, neck swelling°ú hepatomegaly°¡ °üÂûµÇ¾î °Ë»ç¸¦ ÇÏ¿´°í EBV-positive diffuse large B cell lymphomaÀÇ ´Ù Àå±â ħÀ±À¸·Î È®ÀεǾú½À´Ï´Ù. ¸·»ó ½Äµµ´Â Á¤»óÀ̾ú½À´Ï´Ù.

B ¼¼Æ÷ ¸²ÇÁÁ¾ÀÎÁö, T ¼¼Æ÷ ¸²ÇÁÁ¾ÀÎÁö ±¸ºÐÀÌ ¾î·Á¿î Áõ·Ê. Ãʱ⿡´Â ¾Æ·¡¿Í °°Àº ¼Ò°ßÀ¸·Î 'T cell / histiocyte rich large B-cell lymphoma'·Î Æò°¡ÇÏ¿´´Âµ¥ Àåõ°øÀÌ ¹ß»ýÇÏ¿© ¼ö¼úÇÑ ÈÄ¿¡´Â PTCL·Î ÆǴܵǾúÀ½.
À§ Á¶Á÷°Ë»ç: EXTRANODAL MARGINAL ZONE LYMPHOMA OF MALT with large cell component, focal. H. pylori identified.
Lymph node: supraclavicular node, right, biopsy: T cell / histiocyte rich large B-cell lymphoma
Bone marrow: Infiltration of many small T-lymphocytes with a few B lymphocytes, suggestive of involvement of T-cell/histiocyte rich large B cell lymphoma (tumor volume: 60%)


[References]

1) Diffuse large B cell lymphoma (DLBCL, DLBL) ¹Ì¸¸¼º °Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾

2) MALToma ¸»Æ®¸²ÇÁÁ¾

3) Mantle cell lymphoma

4) Peripheral T cell lymphoma (PTCL)

5) NK T-cell lymphoma

6) Burkitt lymphoma ¹öŶ ¸²ÇÁÁ¾

7) Primary gastric lymphoblastic lymphoma

8) Primary gastric Hodgkin's lymphoma

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.